The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation
Catheterization and Cardiovascular Interventions Dec 01, 2017
Silaschi M, et al. - In this article, researchers aimed to report 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve (the JenaValve) for aortic regurgitation (AR). In this study, through a clipping mechanism, the JenaValve overcame technical challenges of transcatheter aortic valve replacement in AR. In view of the low rate of THV embolization, residual AR and permanent pacemaker implantation, using the JenaValve for predominant AR seemed to have satisfactory outcomes. One-year results using the JenaValve for AR encourage its use for this indication.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
